CTNNB1 and adrenal cortex carcinoma: Notably, no patients in the KB-metabolic subtype harbor TP53 mutations (0/14 vs. 7/21), with more patients bearing CTNNB1 mutations (3/14 vs. 2/21) than glycolytic subtype in ACC.